Abstract
Hepatocellular carcinoma (HCC) is a common lethal disease in Asia and there is no effective chemotherapy. Identification of new effective drugs in the treatment of inoperable HCC is urgently need. This is a phase II clinical study to investigate the efficacy, toxicity and pharmacokinetics of paclitaxel in HCC patients. Twenty patients with measurable, unresectable HCC, normal serum bilirubin, normal bone marrow and renal functions were studied. Paclitaxel 175 mg m(-2) was given intravenously over 3 h every 3 weeks. No complete or partial responses were observed. Five patients had stable disease. Major treatment toxicities (grade 3-4) were neutropenia (25%), thrombocytopenia (15%), infection (10%) and allergy (10%). Treatment-related deaths occurred in two patients. The median survival was 12 weeks (range 1-36). Paclitaxel is metabolized by the liver and the pharmacokinetics of paclitaxel in cancer patients with liver involvement or impairment may be important clinically. Pharmacokinetic study was completed in 13 HCC patients. The paclitaxel area under the curve was significantly increased (P < 0.02), clearance decreased (P < 0.02) and treatment-related deaths increased (P = 0.03) in patients with hepatic impairment. In conclusion, paclitaxel in this dose and schedule has no significant anti-cancer effect in HCC patients. Paclitaxel should be used with caution in cancer patients with liver impairment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chao, Y., Chan, WK., Birkhofer, M. et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78, 34–39 (1998). https://doi.org/10.1038/bjc.1998.438
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.438
This article is cited by
-
Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review
Clinical Pharmacokinetics (2018)
-
Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro
Scientific Reports (2016)
-
Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research
BMC Medical Genomics (2015)
-
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib
Cancer Chemotherapy and Pharmacology (2011)
-
Efficacy and safety of viscum fraxini-2 in advanced hepatocellular carcinoma: a phase II study
The Chinese-German Journal of Clinical Oncology (2010)